These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 28112281)
21. The promise of open innovation in drug discovery: an industry perspective. Rees S Future Med Chem; 2015; 7(14):1835-8. PubMed ID: 26420551 [No Abstract] [Full Text] [Related]
22. The importance of synthetic chemistry in the pharmaceutical industry. Campos KR; Coleman PJ; Alvarez JC; Dreher SD; Garbaccio RM; Terrett NK; Tillyer RD; Truppo MD; Parmee ER Science; 2019 Jan; 363(6424):. PubMed ID: 30655413 [TBL] [Abstract][Full Text] [Related]
23. The PCAST report on pharmaceutical innovation: implications for the FDA. Woodcock J Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215 [TBL] [Abstract][Full Text] [Related]
24. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics. Hogarth S Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300 [TBL] [Abstract][Full Text] [Related]
26. Models for open innovation in the pharmaceutical industry. Schuhmacher A; Germann PG; Trill H; Gassmann O Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183 [TBL] [Abstract][Full Text] [Related]
27. [Innovation in pharmaceutical and health biotechnology industries: challenges for a virtuous agenda]. Vargas M; Gadelha CA; Costa LS; Maldonado J Rev Saude Publica; 2012 Dec; 46 Suppl 1():37-40. PubMed ID: 23532311 [TBL] [Abstract][Full Text] [Related]
28. Health assessment of innovative ecological rainforest in pharmaceutical industry: Case study of Zhejiang, China. Dong Y; Xiang Z; Lu H; Zhang L; Zhao Z PLoS One; 2023; 18(2):e0281398. PubMed ID: 36763608 [TBL] [Abstract][Full Text] [Related]
29. Medicine and pharmacy--facts and myths about the development of an innovative pharmaceutical industry in Poland. Kubiak W Sci Eng Ethics; 2005 Jan; 11(1):41-51. PubMed ID: 15726998 [TBL] [Abstract][Full Text] [Related]
30. How to revive breakthrough innovation in the pharmaceutical industry. Munos BH; Chin WW Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677 [TBL] [Abstract][Full Text] [Related]
31. Open innovation and intellectual property: time for a reboot? Judd DB Drug Discov Today; 2013 Oct; 18(19-20):907-9. PubMed ID: 23958455 [No Abstract] [Full Text] [Related]
32. Keynote review: Is declining innovation in the pharmaceutical industry a myth? Schmid EF; Smith DA Drug Discov Today; 2005 Aug; 10(15):1031-9. PubMed ID: 16055019 [TBL] [Abstract][Full Text] [Related]
33. Research and development productivity map: visualization of industry status. Shimura H; Masuda S; Kimura H J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433 [TBL] [Abstract][Full Text] [Related]
34. Why and how have drug discovery strategies in pharma changed? What are the new mindsets? Mignani S; Huber S; Tomás H; Rodrigues J; Majoral JP Drug Discov Today; 2016 Feb; 21(2):239-49. PubMed ID: 26376356 [TBL] [Abstract][Full Text] [Related]
35. The PCAST report: impact and implications for the pharmaceutical industry. Morris SA; Rosenblatt M; Orloff JJ; Lewis-Hall F; Waldstreicher J Clin Pharmacol Ther; 2013 Sep; 94(3):300-2. PubMed ID: 23963216 [TBL] [Abstract][Full Text] [Related]
37. Managing scientific, technical and regulatory innovation in regulated bioanalysis: a discussion paper from the European Bioanalysis Forum. Timmerman P; Henderson N; Smeraglia J; Mulder H; Ingelse B; Brudny-Kloeppel M; Companjen A Bioanalysis; 2013 Jan; 5(2):139-45. PubMed ID: 23330557 [TBL] [Abstract][Full Text] [Related]
38. Value networks identify innovation in 21st century pharmaceutical research. Edwards PJ Drug Discov Today; 2009 Jan; 14(1-2):68-77. PubMed ID: 18973823 [TBL] [Abstract][Full Text] [Related]
39. Is the United States still dominant in the global pharmaceutical innovation network? Hu Y; Scherngell T; Man SN; Wang Y PLoS One; 2013; 8(11):e77247. PubMed ID: 24223710 [TBL] [Abstract][Full Text] [Related]